atezolizumab + regorafenib + AB928

This is an experimental **combination therapy** comprising three agents: - **Atezolizumab**: a humanized IgG1 monoclonal antibody targeting programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to promote antitumor immune responses. FDA approved for several malignancies as monotherapy and in specific combinations. - **Regorafenib**: a multi-kinase inhibitor targeting angiogenic, stromal, and oncogenic receptor tyrosine kinases; used in colorectal cancer and other solid tumors. - **AB928 (etrumadenant)**: a clinical-stage, small-molecule dual antagonist designed to block adenosine receptors A2aR and A2bR, counteracting the immunosuppressive tumor microenvironment created by extracellular adenosine in cancer. This triple therapy aims to synergistically enhance antitumor immunity: atezolizumab relieves immune inhibition via PD-L1 blockade, regorafenib impairs tumor growth and angiogenesis, and AB928 blocks adenosine-mediated suppression of immune cell activation—potentially improving outcomes for refractory or metastatic cancers, with emphasis on colorectal cancer[4][6][8].

Other names

etrumadenant + atezolizumab + regorafenib